Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1021-335X Online ISSN: 1791-2431
Journal Cover
August 2013 Volume 30 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August 2013 Volume 30 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells

  • Authors:
    • Eun Jin Lim
    • Chul-Ho Oak
    • Jeonghoon Heo
    • Young-Ho Kim
  • View Affiliations / Copyright

    Affiliations: Department of Molecular Biology and Immunology, Kosin University College of Medicine, Busan, Republic of Korea, Department of Internal Medicine, Kosin University College of Medicine, Busan, Republic of Korea
  • Pages: 856-862
    |
    Published online on: May 24, 2013
       https://doi.org/10.3892/or.2013.2494
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Combined treatment with a photosensitizer and iodide laser [photodynamic therapy (PDT)] has improved the outcome of various cancers. In this study, we investigated the effects of using the photosensitizer methylene blue (MB) in PDT in human lung adenocarcinoma cells. We found that MB enhances PDT-induced apoptosis in association with downregulation of anti-apoptotic proteins, reduced mitochondrial membrane potential (MMP), increased phosphorylation of the mitogen-activated protein kinase (MAPK) and the generation of reactive oxygen species (ROS). In MB-PDT-treated A549 cells, we observed PARP cleavage, procaspase-3 activation, downregulation of the anti-apoptotic proteins Bcl-2 and Mcl-1, and the reduction of mitochondrial membrane potential (MMP). Western blot data showed that phosphorylation of p38 was increased in MB-PDT-treated A549 cells, indicating that several signaling molecules participate in the apoptotic cascade. Our data also showed that apoptotic cell death in MB-PDT-treated cells occurred through a series of steps beginning with the photochemical generation of ROS. Demonstrating the role of ROS, pretreatment of A549 cells with the antioxidant N-acetylcysteine (NAC) followed by MB-PDT resulted in increased cell viability and reduced proteolytic cleavage of PARP.

Introduction

Photodynamic therapy (PDT) is an emerging treatment for a variety of cancers and other diseases. In PDT the activation of a photosensitizer by a specific wavelength of light in the presence of oxygen promotes cellular damage (1,2). Currently, several research groups are developing PDT technology. A variety of photosensitizers such as Photofrin®, ALA and cisplatin have shown promising results (1–3). However, improvements in quantum efficiency, reductions in toxicity and the ability to specifically target a highly effective dose have not been fully attained with current PDT technologies.

Methylene blue (MB), a well-known dye with high light absorption at 665 nm, is effective in PDT due to its ability to generate singlet oxygen and its proven photodynamic activity in clinical applications against several diseases (4–6). Previous studies have documented the effectiveness of MB-PDT against melanoma in cell culture, and MB-PDT has been used to efficiently treat relatively large melanoma lesions not eligible for surgery (6). In addition, some researchers have reported that MB is more toxic to leukemia cells than to normal PBMCs (7). This suggests that MB is more toxic in cancer cells than normal cells, a potential benefit in reducing unwanted toxicity due to PDT.

Although it has been documented that in MB-PDT the derivative of MB induces apoptosis in several cell lines (8), the current understanding of the mechanisms of apoptosis induced by MB-PDT is limited. Currently recognized mechanisms of apoptosis associated with MB-PDT include the induction of DNA damage, the generation of reactive oxygen species (ROS), and possibly mitochondrial damage (9,10). Published data have indicated mitochondrial damage in MB-PDT-induced tumor regression because MB is likely to bind to the negative electrochemical environment of the mitochondrial matrix in melanoma and HeLa cells (11–13). A better understanding of the mechanisms of apoptosis induced by MB-PDT will help inform cancer therapeutic strategies.

In this study, we investigated the role of MB in PDT-induced apoptosis in human lung adenocarcinoma cells. We found that MB sensitizes A549 cells to PDT-induced apoptosis, suggesting that MB-PDT may provide an effective therapeutic strategy for lung adenocarcinoma. In addition, we found that caspase activation, downregulation of anti-apoptotic proteins, reduced mitochondrial membrane potential (MMP), activation of the mitogen-activated protein kinase (MAPK) p38, and ROS generation critically contribute to the anticancer effect of MB-PDT.

Materials and methods

Reagents

The methylene blue (MB) used for PDT was acquired from Aldrich (Milwaukee, WI, USA), and RPMI-1640 medium was purchased from Hyclone (Logan, UT, USA). Antibodies against PARP-1, Bcl-2, Bcl-xL, Mcl-1, and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and anti-phospho-JNK, anti-phospho-p38, and anti-phospho-ERK were purchased from Cell Signaling (Beverly, MA, USA). Benzyl carbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) was purchased from Biomol (Plymouth Meeting, PA, USA), 2′7′-dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased from Molecular Probes (Eugene, OR, USA), and N-acetylcysteine (NAC) and all other chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell culture and chemical treatments

Human lung adenocarcinoma cells (A549 cells) were obtained from the American Type Culture Collection (Rockville, MD, USA). The A549 cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 U/ml) at 37ºC in a humidified incubator with 5% CO2 and 95% air. When the cells were subconfluent, the medium was replaced with fresh medium and 0.1–2.0 μg/ml of MB was added to the culture medium for 1 h. The cells were then irradiated with 650 nm light produced by a dye laser (Red Diode Laser) at 30–120 Joules (J).

Cellular viability assay

For the morphological evaluation of cell death, approximately 5×105 A549 cells were plated into 60-mm cell culture dishes overnight. For the trypan blue exclusion assay, trypsinized cells were pelleted and resuspended in 0.2 ml of medium, 0.5 ml of 0.4% trypan blue solution, and 0.3 ml of phosphate-buffered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min, and examined under a light microscope. At least 300 cells were counted for each survival determination.

Western blot analysis

For western blot analyses, A549 cells were lysed with 1X Laemmli lysis buffer (2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M SDS, 0.3 mM bromophenol blue) and boiled for 10 min. Protein content was measured with the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples were diluted with 1X Laemmli lysis buffer containing 1.28 M β-mercaptoethanol, and equal amounts of protein were loaded on 8–12% SDS-polyacrylamide gels. Proteins were separated by SDS-PAGE and electrophoretically transferred to a nitrocellulose membrane. The nitrocellulose membrane was blocked with 5% nonfat dry milk in PBS-Tween-20 (0.1%, v/v) for 1 h. The membrane was incubated with primary antibody (diluted according to the manufacturer's instructions) at room temperature for 1.5 h. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington Heights, IL, USA). To ensure equal protein loading, each nitrocellulose membrane was stripped and reprobed with an anti-actin antibody after the experiment was completed.

DNA fragmentation and DAPI staining assay

To assess for DNA fragmentation after MB and/or PDT for 24 h, ~1×106 treated A549 cells were lysed for 30 min on ice in buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA and 0.5% Triton X-100. Lysates were vortexed and cleared by centrifugation at 12,000 × g for 30 min. Fragmented DNA in the supernatant was extracted with an equal volume of a mixture of neutral phenol:chloroform:isoamyl alcohol (25:24:1) and analyzed electrophoretically on 1.5% agarose gels containing 0.1 g/ml EtBr. The cells were fixed on slide glass through the application of 4% paraformaldehyde for 30 min at room temperature. After washing with PBS, 300 nM 4′, 6′-diamidino-2-phenylindole (DAPI) was added to the fixed cells for 10 min, after which they were examined by fluorescence microscopy. Apoptotic cells were identified by condensation and fragmentation of nuclei. All DAPI staining experiments were performed in duplicate.

Measurement of reactive oxygen species

The generation of ROS was measured by staining with 2′,7′-dichlorofluorescein diacetate (DCF-DA). Briefly, A549 cells were seeded in six-well plates (1×105 cells per well), allowed to attach overnight and treated with MB and/or PDT. The cells were stained with 20 μM DCF-DA for 30 min at 37ºC and fluorescence was detected by a fluorescence microscope.

JC-1 mitochondrial membrane potential assay

To monitor MMP, JC-1 dye was used as previously described (14). In cells with undamaged mitochondria, the aggregated dye appears as red fluorescence, whereas in cells with altered MMP that are undergoing apoptosis, the dye remains as monomers in the cytoplasm and emits diffuse green fluorescence. The red/green fluorescence ratio is dependent on MMP. After A549 cells were treated with MB and PDT, they were stained with a JC-1 MMP detection kit for 10 min and analyzed by flow cytometry. The fluorescence intensity was measured with the FACScan flow cytometer (Beckman Coulter, Inc., Hialeah, FL, USA).

Statistical analysis

All experiments were repeated three or more times. The results are represented as means ± standard deviations (SDs). The difference between two mean values was analyzed using Student's t-test and was considered statistically significant at p<0.05.

Results

Methylene blue promotes PDT-mediated A549 cell toxicity

To evaluate the effects of MB-PDT on cell viability, A549 cells were treated with various concentrations of MB and/or PDT (30 and 60 J) for 24 h and a trypan blue assay was performed. As shown in Fig. 1, while MB alone had little effect on cell viability, MB treatment followed by PDT significantly decreased cell viability as determined by trypan blue exclusion (Fig. 1A) and DAPI staining (Fig. 1B). These results suggest that PDT enhances the toxicity of MB in A549 cells.

Figure 1

Cytotoxicity of MB and PDT in A549 cells. (A) A549 cells were treated with the indicated concentrations of MB followed by laser irradiation (30 and 60 J). A trypan blue assay was then used to measure cell viability. *p<0.05 compared with MB-treated cells (B) A549 cells after DAPI staining. A549 cells were fixed, washed with PBS, stained with DAPI and examined by fluorescence microscopy. Data are expressed as the mean ± SD of three independent experiments.

Methylene blue promotes PDT-induced apoptosis by caspase activation

To address the significance of caspase activation in MB-PDT-induced apoptosis, we examined caspase activity after MB-PDT. Treatment of A549 cells with various concentrations of MB and PDT resulted in a dramatic increase in the cleavage of PARP, a caspase substrate, and in the cleavage of procaspase-3 (Fig. 2A) in a time-dependent manner (Fig. 2B). In order to confirm that the activation of caspases is a key step in MB-PDT-induced apoptosis, the A549 cells were pretreated with z-VAD-fmk (25 μM), a cell-permeable caspase inhibitor, followed by MB-PDT for 24 h. As shown in Fig. 2C, MB-PDT-induced apoptosis was prevented by pretreatment with z-VAD-fmk, as indicated by the reduced PARP cleavage. We also found that z-VAD-fmk prevented the dose-dependent increase in the accumulation of apoptotic DNA after treatment with MB-PDT (Fig. 2D). These results suggest that MB-PDT-induced cell death is associated with caspase activation.

Figure 2

Effects of MB-PDT on caspase activation in A549 cells. (A) A549 cells were treated with the indicated concentrations of MB before PDT and incubated for 24 h. Equal amounts of cell lysates (20 μg) were subjected to electrophoresis and analyzed by western blotting for PARP, procaspase-3 and actin. (B) A549 cells were treated with MB (2 μg/ml) or PDT (60 J) or both for various time periods. Equal amounts of cell lysates (20 μg) were subjected to electrophoresis and analyzed by western blotting for PARP and actin. (C) A549 cells were pre-incubated with 25 μM z-VAD-fmk for 1 h before combined treatment with MB and PDT for 24 h. Equal amounts of cell lysates (20 μg) were subjected to electrophoresis and analyzed by western blotting for PARP and actin. (D) A549 cells were pre-incubated with 25 μM z-VAD-fmk for 1 h before combined treatment with MB and PDT for 24 h. Fragmented DNA was extracted and analyzed on a 2% agarose gel.

MB and PDT induce downregulation of anti-apoptotic proteins and loss of mitochondrial membrane potential in A549 cells

We further examined whether MB-PDT-induced apoptosis is associated with the modulation of apoptosis regulatory proteins. As shown in Fig. 3A, exposure of A549 cells to MB and PDT led to a slight decrease in Bcl-xL. However, levels of Bcl-2 and Mcl-1 in A549 cells were markedly reduced by MB and PDT in a dose-dependent manner. We assessed MMP in order to determine the role of mitochondrial damage in MB-PDT-induced apoptosis of A549 cells. As shown in Fig. 3B, we found that exposure of A549 cells to MB and PDT significantly reduced MMP in a dose-dependent manner. The proportion of cells with a loss of MMP substantially increased with MB treatment (1 and 2 μg/ml) plus PDT (60 J).

Figure 3

Effects of MB and PDT on anti-apoptotic protein expression and mitochondrial function in A549 cells. (A) The levels of apoptosis-related protein expression was analyzed after treatment with MB and/or PDT in A549 cells. Equal amounts of whole cell lysate (20 μg) were subjected to electrophoresis and analyzed by western blotting for Bcl-2, Bcl-xL and Mcl-1. Western blotting of actin served as an internal control. (B) Loss of MMP following treatment with MB and/or PDT. A549 cells were treated with MB or PDT or both for 24 h, then incubated with JC-1 for 1 h. Fluorescence was measured by flow cytometry.

Activation of p38 signaling plays an important role in MB-induced photosensitization in A549 cells

In order to investigate whether a MAPK signaling pathway was involved in cell death in A549 cells treated with MB-PDT, we examined the phosphorylation of p38, JNK and ERK in A549 cells after MB and/or PDT. As shown in Fig. 4A, p38 activity was increased slightly at 2 h after MB application (2 μg/ml) and the increased p38 activity was sustained after 8 h of treatment with MB alone, whereas a much stronger and prolonged activation of p38 was observed after combined treatment with MB and PDT. To further confirm the involvement of the p38 signaling pathway in MB-PDT-induced apoptosis, we applied specific inhibitors of JNK (SP600125), p38 (SB203589), and ERK (PD98059). Pretreatment of A549 cells with the p38 inhibitor SB203589 before MB-PDT increased cell viability (Fig. 4B) and reduced proteolytic cleavage of PARP (Fig. 4C). Taken together, these results suggest that the prolonged activation of the MAPK p38 pathway plays an important role in MB-induced photosensitization.

Figure 4

Effects of MB and PDT on the p38 MAPK signaling pathway. (A) A549 cells were treated with MB (2 μg/ml) and/or PDT (60J) for various time periods. Levels of phosphorylated p38, JNK and ERK were detected by western blotting using specific p-p38, p-JNK and p-ERK antibodies. (B) A549 cells were pretreated with specific inhibitors of JNK (SP600125), p38 (SB203589) and ERK (PD98059) at the indicated concentration and further treated with 2 μg/ml of MB and PDT for 24 h. Cell viability was then assessed by trypan blue assay. *p<0.05 compared with MB+PDT treated cells (C) A549 cells were pretreated with SB203589 at the indicated concentration and further treated with 2 μg/ml of MB and PDT for 24 h. Equal amounts of whole cell lysates were subjected to electrophoresis and analyzed by western blotting for PARP, and actin served as a loading control.

MB potentiates PDT-induced ROS generation, which is attenuated by the addition of antioxidants to A549 cells

ROS are byproducts of the normal metabolism of oxygen, and they are generated by various environmental stresses such as drugs, UV light and heat shock. ROS play an important role in apoptosis under both physiologic and pathologic conditions (15,16). Therefore, we examined whether ROS generation was involved in MB-induced photosensitization of A549 cells by measuring the intracellular hydrogen peroxide level in A549 cells after MB-PDT. As shown in Fig. 5A, the combination of MB and PDT markedly increased intracellular hydrogen peroxide levels in A549 cells. We next investigated whether ROS generation was directly associated with MB-PDT-induced apoptosis. Pretreatment with NAC, a well-known antioxidant, markedly increased cell viability after MB-PDT (Fig. 5B). Moreover, apoptosis induced by MB-PDT was markedly attenuated by pretreatment with NAC (Fig. 5C). Taken together, these results indicate that MB-induced photosensitization and MB-PDT-induced apoptosis are mediated by the generation of ROS.

Figure 5

Effects of MB and PDT on ROS generation in A549 cells. (A) A549 cells were pre-incubated in the absence or presence of MB (1 μg/ml) for 1 h and subsequently treated with or without a PDT (60 J) for 24 h. Cells were then incubated with 20 μM DCFDA at 37ºC for 30 min and ROS generation was measured using a flow cytometer or a fluorescence microscope. (B) A549 cells were pre-incubated in the presence or absence of NAC (10 mM) for 1 h and subsequently treated with or without MB plus an iodide laser for 24 h. Cell viability was then assessed by a trypan blue assay. *p<0.05 compared with MB+PDT-treated cells. (C) A549 cells were pre-incubated in the presence or absence of NAC (10 mM) and subsequently treated with MB (1 μg/ml) and a PDT (60 J) for 24 h. Equal amounts of whole cell lysates (20 μg) were subjected to electrophoresis and analyzed by western blotting for PARP, and actin served as a loading control.

Discussion

Although PDT is a commonly applied cancer therapy, its efficacy is limited by injury to healthy tissue, varying tumor sensitivity and various other side effects. Therefore, novel therapeutic strategies are needed to selectively induce the death of cancer cells while sparing normal cells. Recently, many attempts to improve the therapeutic effects of PDT have been reported (17) and several photosensitizers such as porfimer sodium (Photofrin), ALA and cisplatin have been used to enhance tumor cell death in PDT (18,19). In this study, we found that MB effectively sensitizes A549 human lung adenocarcinoma cells to PDT-induced apoptosis through caspase activation, downregulation of anti-apoptotic proteins, reduced MMP, activation of p38 signaling pathways and increased ROS.

MB is already approved for systemic administration by intravenous injection for clinical use in patients with other diseases. It has various biological applications, it is used as a staining dye for parathyroid tissue (20), an antifungal agent in goldfish, and an antimalarial agent (21). In the present study, we showed that compared with MB or PDT alone, the combination of MB and PDT resulted in significantly enhanced A549 cell death (Fig. 1). This enhancement of PDT-induced apoptosis by MB was dependent on caspase activation, since z-VAD-fmk, a caspase inhibitor, reduced the cell death induced by MB-PDT (Fig. 2).

Mitochondria play an important role in apoptotic pathways that result from a variety of intracellular events including the release of caspase activators, changes in MMP, ROS generation, and changes in the Bcl-2 family of proteins (22). In the current study, loss of MMP was observed in A549 cells co-treated with MB and PDT (Fig. 3). Levels of Bcl-2 in A549 cells were also markedly decreased by MB-PDT. Taken together, these results suggest that the mitochondrial pathway is involved in the enhancement of PDT-induced apoptosis by MB.

The activation of MAPK pathways plays an essential role in apoptosis induced by many cellular stresses. The p38 MAPK is activated by ROS in many cells treated with radiation, anticancer drugs, and chemopreventive agents (23). In our study, MB-PDT-treated A549 cells showed remarkably activated p38, but not JNK or ERK MAPK (Fig. 4). Pretreatment of A549 cells with the p38 inhibitor SB203589 prevented MB-PDT-induced apoptosis. These results suggest that activation of the p38 MAPK pathway contributes to MB-PDT-induced apoptosis in A549 cells.

ROS are generated by many environmental stresses (e.g., UV light and heat shock), and they are produced as a normal product of cellular metabolism (e.g., phagocytosis). ROS play an important role in apoptosis induction under both physiologic and pathologic conditions (16). In the current study, we show that co-treatment with MB and PDT induced ROS generation in A549 cells. Furthermore, antioxidant (NAC) pretreatment attenuated ROS generation and MB-PDT-induced apoptosis (Fig. 4), suggesting that the elevation of ROS levels by combined treatment with MB and PDT plays an important role in enhancing the apoptotic susceptibility of A549 cells.

In conclusion, the present study shows that MB enhances PDT-induced apoptosis in human lung adenocarcinoma cells via caspase activation, reductions in anti-apoptotic protein levels, loss of MMP, activation of the p38 MAPK signaling pathway and ROS generation. Therefore, a combined regimen of MB and PDT may offer a better therapeutic strategy to enhance photosensitivity in tumor cells.

Acknowledgements

This work was supported by Basic Science Research Program through the NRF funded by the Ministry of Education, Science and Technology (2011-0004206) and a grant from Kosin University College of Medicine (2011) and a grant from Institute for Medical Sciences (2011).

References

1 

Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic therapy. J Natl Cancer Inst. 90:889–905. 1998. View Article : Google Scholar

2 

Dolmans DE, Fukumura D and Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003. View Article : Google Scholar

3 

Sharman WM, Allen CM and van Lier JE: Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today. 4:507–517. 1999. View Article : Google Scholar : PubMed/NCBI

4 

Bisland SK, Chien C, Wilson BC and Burch S: Pre-clinical in vitro and in vivo studies to examine the potential use of photodynamic therapy in the treatment of osteomyelitis. Photochem Photobiol Sci. 5:31–38. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Tardivo JP, Del Giglio A, Paschoal LH and Baptista MS: New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma. Photomed Laser Surg. 24:528–531. 2006. View Article : Google Scholar : PubMed/NCBI

6 

Wagner M, Suarez ER, Theodoro TR, Machado Filho CD, Gama MF, Tardivo JP, Paschoal FM and Pinhal MA: Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases. Clin Exp Dermatol. 37:527–533. 2012. View Article : Google Scholar

7 

Kirszberg C, Rumjanek VM and Capella MA: Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy. Cancer Chemother Pharmacol. 56:659–665. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Ball DJ, Luo Y, Kessel D, Griffiths J, Brown SB and Vernon DI: The induction of apoptosis by a positively charged methylene blue derivative. J Photochem Photobiol B. 42:159–163. 1998. View Article : Google Scholar : PubMed/NCBI

9 

Noodt BB, Rodal GH, Wainwright M, Peng Q, Horobin R, Nesland JM and Berg K: Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells. Int J Cancer. 75:941–948. 1988. View Article : Google Scholar : PubMed/NCBI

10 

Rodrigues T, de França LP, Kawai C, de Faria PA, Mugnol KC, Braga FM, Tersariol IL, Smaili SS and Nantes IL: Protective role of mitochondrial unsaturated lipids on the preservation of the apoptotic ability of cytochrome C exposed to singlet oxygen. J Biol Chem. 282:25577–25587. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Gabrielli D, Belisle E, Severino D, Kowaltowski AJ and Baptista MS: Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions. Photochem Photobiol. 79:227–232. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Chen Y, Zheng W, Li Y, Zhong J, Ji J and Shen P: Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics. Cancer Sci. 99:2019–2027. 2008.PubMed/NCBI

13 

Lu Y, Jiao R, Chen X, Zhong J, Ji J and Shen P: Methylene blue-mediated photodynamic therapy induces mitochondria-dependent apoptosis in HeLa cell. J Cell Biochem. 105:1451–1460. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Kim MJ, Lee TH, Kim SH, Choi YJ, Heo J and Kim YH: Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int J Oncol. 37:1177–1185. 2010.PubMed/NCBI

15 

Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794–798. 1991.PubMed/NCBI

16 

Simon HU, Haj-Yehia A and Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Firczuk M, Winiarska M, Szokalska A, Jodlowska M, Swiech M, Bojarczuk K, Salwa P and Nowis D: Approaches to improve photodynamic therapy of cancer. Front Biosci. 16:208–224. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Nahabedian MY, Cohen RA, Contino MF, Terem TM, Wright WH, Berns MW and Wile AG: Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst. 80:739–743. 1988. View Article : Google Scholar : PubMed/NCBI

19 

Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE and Nesland JM: Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 61:5824–5832. 2001.PubMed/NCBI

20 

Sherlock DJ and Holl-Allen RT: Intravital methylene blue staining of parathyroid glands and tumours. Ann R Coll Surg Engl. 66:396–398. 1984.PubMed/NCBI

21 

Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, Mikus G, Burhenne J, Riedel KD, Schirmer RH, Kouyaté B and Müller O: Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J. 5:842006. View Article : Google Scholar : PubMed/NCBI

22 

Yang ES, Choi MJ, Kim JH, Choi KS and Kwon TK: Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. Toxicol In Vitro. 25:1803–1810. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Chen YR and Tan TH: The c-Jun N-terminal kinase pathway and apoptotic signaling. Int J Oncol. 16:651–662. 2000.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Lim EJ, Oak C, Heo J and Kim Y: Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells. Oncol Rep 30: 856-862, 2013.
APA
Lim, E.J., Oak, C., Heo, J., & Kim, Y. (2013). Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells. Oncology Reports, 30, 856-862. https://doi.org/10.3892/or.2013.2494
MLA
Lim, E. J., Oak, C., Heo, J., Kim, Y."Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells". Oncology Reports 30.2 (2013): 856-862.
Chicago
Lim, E. J., Oak, C., Heo, J., Kim, Y."Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells". Oncology Reports 30, no. 2 (2013): 856-862. https://doi.org/10.3892/or.2013.2494
Copy and paste a formatted citation
x
Spandidos Publications style
Lim EJ, Oak C, Heo J and Kim Y: Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells. Oncol Rep 30: 856-862, 2013.
APA
Lim, E.J., Oak, C., Heo, J., & Kim, Y. (2013). Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells. Oncology Reports, 30, 856-862. https://doi.org/10.3892/or.2013.2494
MLA
Lim, E. J., Oak, C., Heo, J., Kim, Y."Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells". Oncology Reports 30.2 (2013): 856-862.
Chicago
Lim, E. J., Oak, C., Heo, J., Kim, Y."Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells". Oncology Reports 30, no. 2 (2013): 856-862. https://doi.org/10.3892/or.2013.2494
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team